VEGFA and diabetic macular edema: Current primary therapy for DME is aimed at stabilizing damage, leaking blood vessels by administration of antivascular endothelial growth factor (VEGF) agents into the vitreous when clinically significant diabetic macular edema (CSDME) is present.